

## **MedAnnex to receive Scottish Enterprise funding.**

**Edinburgh, Scotland, 11th January 2016.**

MedAnnex is delighted to announce that it is to receive funding from Scottish Enterprise, via SMART: SCOTLAND.

The SMART scheme provides grants to carefully selected Small to Medium Enterprises based in Scotland, to help fund research and development projects that have a commercial endpoint.

MedAnnex Chairman Professor Chris Wood commented *'We are enormously pleased to receive support in this way from Scottish Enterprise. The grant will help with the continued development of our lead antibody, Annexuzlimab<sup>®</sup>, as an innovative treatment for people with autoimmune diseases.'*

### About Scottish Enterprise

Scottish Enterprise is a non-departmental public body of the Scottish Government committed to encouraging Scotland's economic development through investment, internationalisation, innovation and inclusive growth.

### About MedAnnex

MedAnnex Ltd, based in Scotland, is a dynamic biotechnology company developing new treatments for people with autoimmune diseases. MedAnnex's novel monoclonal antibody, Annexuzlimab,<sup>®</sup> has shown significant activity in disease experimental models, including rheumatoid arthritis, multiple sclerosis and systemic lupus erythematosus.